Biomea Fusion, Inc. (BMEA) stock
BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.56−0.05 (-7.89%)
Close on Nov 12, 2026Market cap $40.79MP/E –Yield –
Biomea Fusion r&d expenses
Research and development expenses are spending on new products and technology.
Biomea Fusion's R&D Expenses for the twelve months ending Sep 30, 2026 was $34.91M, down 55.9% year over year. For fiscal 2025 it was $61.98M, down 47.5% from the year before. The highest annual figure on record is $118.09M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.98M | -47.5% |
| FY2024 | Dec 31, 2024 | $118.09M | +15.2% |
| FY2023 | Dec 31, 2023 | $102.55M | +63.5% |
| FY2022 | Dec 31, 2022 | $62.71M | +124.0% |
| FY2021 | Dec 31, 2021 | $28.00M | +662.6% |
| FY2020 | Dec 31, 2020 | $3.67M | +236.2% |
| FY2019 | Dec 31, 2019 | $1.09M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.53M | -40.8% |
| Q2 FY2026 | Jun 30, 2026 | $9.14M | -44.8% |
| Q1 FY2026 | Mar 31, 2026 | $9.12M | -60.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.12M | -67.8% |
| Q3 FY2025 | Sep 30, 2025 | $14.40M | -47.1% |
| Q2 FY2025 | Jun 30, 2025 | $16.57M | -47.9% |
| Q1 FY2025 | Mar 31, 2025 | $22.90M | -32.2% |
| Q4 FY2024 | Dec 31, 2024 | $25.24M | -18.2% |
| Q3 FY2024 | Sep 30, 2024 | $27.24M | +7.5% |
| Q2 FY2024 | Jun 30, 2024 | $31.83M | +45.1% |
| Q1 FY2024 | Mar 31, 2024 | $33.78M | +38.5% |
| Q4 FY2023 | Dec 31, 2023 | $30.87M | +50.3% |
| Q3 FY2023 | Sep 30, 2023 | $25.35M | +38.9% |
| Q2 FY2023 | Jun 30, 2023 | $21.94M | +74.4% |
| Q1 FY2023 | Mar 31, 2023 | $24.40M | +114.9% |
| Q4 FY2022 | Dec 31, 2022 | $20.54M | +85.2% |
| Q3 FY2022 | Sep 30, 2022 | $18.24M | +131.3% |
| Q2 FY2022 | Jun 30, 2022 | $12.58M | +140.8% |
| Q1 FY2022 | Mar 31, 2022 | $11.35M | +198.8% |
| Q4 FY2021 | Dec 31, 2021 | $11.09M | +375.5% |
| Q3 FY2021 | Sep 30, 2021 | $7.89M | +899.5% |
| Q2 FY2021 | Jun 30, 2021 | $5.22M | +2318.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.80M | +1037.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.33M | – |
| Q3 FY2020 | Sep 30, 2020 | $789.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $216.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $334.00K | – |
See a number that looks wrong?